Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study.

[1]  A. Coats,et al.  Ethical authorship and publishing. , 2009, International journal of cardiology.

[2]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[3]  Nikolaus Marx,et al.  The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. , 2008, The American journal of cardiology.

[4]  C. Furberg,et al.  Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. , 2008, Journal of the American College of Cardiology.

[5]  C. Gaudio,et al.  Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease. , 2007, The American journal of cardiology.

[6]  J. Després,et al.  Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. , 2007, European heart journal.

[7]  P. Ridker,et al.  Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. , 2007, JAMA.

[8]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[9]  Victor M Montori,et al.  Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. , 2007, Journal of the American College of Cardiology.

[10]  J. Danesh,et al.  Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies , 2007, Circulation.

[11]  Changes in Triglyceride Levels and Risk for Coronary Heart Disease in Young Men , 2007, Annals of Internal Medicine.

[12]  B. G. Brown,et al.  Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials , 2006, Current opinion in lipidology.

[13]  R. Nesto.  Beyond Low-Density Lipoprotein , 2005, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[14]  N. Day,et al.  Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk , 2004, Annals of Internal Medicine.

[15]  R. Peters,et al.  Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study. , 2004, The American journal of medicine.

[16]  Jo Mitchell,et al.  Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study , 2003, Public Health Nutrition.

[17]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[18]  C. Ballantyne,et al.  Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S , 2001, Circulation.

[19]  N. Day,et al.  EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. , 1999, British journal of cancer.

[20]  R. Krauss,et al.  Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. , 1996, JAMA.

[21]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.